NCT04243551View on ClinicalTrials.gov

Prospective, Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Symptomatic CD Patients

PHASE2TerminatedINTERVENTIONAL
Enrollment

83

Participants

Timeline

Start Date

November 1, 2019

Primary Completion Date

October 16, 2023

Study Completion Date

October 31, 2023

Conditions
Celiac Disease
Interventions
DRUG

Latiglutenase

Administered orally (daily)

OTHER

Placebo

Administered orally (daily)

Trial Locations (1)

55905

Mayo Clinic, Rochester

Sponsors
All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

Entero Therapeutics

INDUSTRY